跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

SML2624

Sigma-Aldrich

Dexlansoprazole

≥98% (HPLC)

别名:

(R)-(+)-Lansoprazole, (R)-(+)2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C16H14F3N3O2S
CAS号:
138530-94-6
分子量:
369.36
MDL编号:
MFCD16294176
UNSPSC代码:
12352200
NACRES:
NA.77

方案

≥98% (HPLC)

表单

powder

旋光性

[α]/D +142 to +158°, c = 1 in chloroform-d

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

2-8°C

InChI

1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1

InChI key

MJIHNNLFOKEZEW-RUZDIDTESA-N

生化/生理作用

Dexlansoprazole is a proton pump inhibitor. It is the active enantiomer of lansoprazole used to treat gastroesophageal reflux disease (GERD).
Proton pump inhibitor; Active enantiomer of lansoprazole to treat gastroesophageal reflux disease (GERD)

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000434835
0000434835
0000345407
0000338093
0000345407

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Karen E Hansen et al.
Gastroenterology, 156(4), 926-934 (2018-11-18)
Epidemiological studies have associated proton pump inhibitor (PPI) therapy with osteoporotic fractures, but it is not clear if PPIs directly cause osteoporosis. We evaluated the effect of dexlansoprazole and esomeprazole on bone turnover, bone mineral density (BMD), true fractional calcium
Khean Lee Goh et al.
Journal of neurogastroenterology and motility, 22(3), 355-366 (2016-03-05)
Although gastroesophageal reflux disease is not as common in Asia as in western countries, the prevalence has increased substantially during the past decade. Gastroesophageal reflux disease is associated with considerable reductions in subjective well-being and work productivity, as well as

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持